KPTI
Karyopharm Therapeutics Inc.Company Information
- Company Name
- Karyopharm Therapeutics Inc.
- CIK
- CIK0001503802
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- KPTI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- KPTI
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-09-12
- Last sale
- 2026-09-01
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 40,872
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 19,954,072
- Shares outstanding
- 28,938,000
- Ownership
- 68.95%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -10.05%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 55 | 91 | 61 | 38 | 39 | 39 | 62 | 73 | 85 | 31 | 52 | 44 | ||||||
| Available For Sale Securities Debt Securities Current | 10 | 0 | 3 | 8 | 13 | 31 | 46 | 61 | 67 | 118 | 139 | 165 | ||||||
| Receivables Net Current | 30 | 23 | 26 | 32 | 33 | 35 | 31 | 32 | 38 | 31 | 27 | 38 | ||||||
| Inventory Net | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 3 | 3 | 3 | 3 | ||||||
| Prepaid Expense And Other Assets Current | 7 | 9 | 9 | 8 | 8 | 10 | 12 | 15 | 15 | 15 | 12 | 13 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Assets Current | 106 | 126 | 103 | 90 | 98 | 120 | 156 | 185 | 209 | 198 | 234 | 263 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 3 | 3 | 4 | 4 | 5 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 111 | 131 | 108 | 96 | 105 | 128 | 164 | 189 | 214 | 204 | 240 | 270 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 8 | 4 | 4 | 5 | 3 | 6 | 5 | 6 | 3 | 5 | 3 | 1 | ||||||
| Accrued Liabilities Current | 79 | 76 | 64 | 66 | 63 | 57 | 61 | 50 | 50 | 55 | 61 | 56 | ||||||
| Secured Debt Current | 40 | 32 | 21 | 13 | 6 | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 4 | 4 | 3 | 3 | 3 | ||||||
| Other Liabilities Current | 6 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | ||||||
| Liabilities Current | 134 | 117 | 92 | 87 | 99 | 90 | 92 | 61 | 58 | 65 | 69 | 62 | ||||||
| Convertible Long Term Notes Payable | - | - | - | - | - | - | 0 | - | - | 171 | 171 | 171 | ||||||
| Secured Long Term Debt | 85 | 88 | 95 | 84 | 90 | 95 | 95 | 94 | 94 | - | 0 | - | ||||||
| Operating Lease Liability Noncurrent | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 0 | 1 | 2 | 3 | 4 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 11 | 14 | 8 | 5 | 2 | 6 | 4 | 3 | 1 | 1 | ||||||
| Liabilities | 441 | 397 | 401 | 365 | 344 | 334 | 350 | 349 | 346 | 373 | 377 | 370 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,519 | 1,516 | 1,466 | 1,388 | 1,385 | 1,381 | 1,378 | 1,373 | 1,369 | 1,356 | 1,351 | 1,346 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -1 | -1 | -0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -1,849 | -1,782 | -1,759 | -1,657 | -1,624 | -1,587 | -1,563 | -1,533 | -1,501 | -1,524 | -1,487 | -1,445 | ||||||
| Stockholders Equity | -330 | -266 | -293 | -269 | -239 | -206 | -186 | -160 | -132 | -169 | -136 | -100 | ||||||
| Liabilities And Stockholders Equity | 111 | 131 | 108 | 96 | 105 | 128 | 164 | 189 | 214 | 204 | 240 | 270 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 106 | 106 | 53 | 53 | 53 | 53 | 53 | 400 | 400 | 400 | 400 | 400 | ||||||
| Common Stock Shares Issued | 23 | 23 | 18 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | ||||||
| Shares Outstanding | 23 | 23 | 18 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKaryopharm Therapeutics Inc. (KPTI) — SEC Financial Statements & Analysis
Karyopharm Therapeutics Inc. (KPTI) is a pharmaceutical preparations company, incorporated in DE. Karyopharm Therapeutics Inc. trades on Nasdaq as: KPTI. Karyopharm Therapeutics Inc. (KPTI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Karyopharm Therapeutics Inc. carries a market cap of $282.72M, a P/E ratio of -1.26x, a P/B ratio of -0.86x, a P/S ratio of 1.93x, an enterprise value of $352.78M, and an EV/EBITDA multiple of -4.29x. On profitability, it posts a gross margin of 95.89%, an operating margin of -56.17%, a net margin of -153.28%, a Return on Equity (ROE) of 78.98%, and a Return on Assets (ROA) of -207.90%. Per share, it reports EPS of $-7.77, diluted EPS of $-7.77, free cash flow per share of $-2.26, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 6.81% year-over-year, net income growth of 81.88% year-over-year, and EPS growth of -45.82% year-over-year. On the balance sheet, it maintains a current ratio of 0.79x, a quick ratio of 0.71x, working capital of $-27.86M, a debt-to-equity ratio of -1.34x, a debt ratio of 3.97, an interest coverage ratio of -2.36x, free cash flow of $-65.35M (TTM), and net debt of $70.06M. Figures sourced from SEC EDGAR.
- Market Cap
- $282.72M
- P/E TTM
- -1.26x
- EPS TTM
- $-7.77
- P/B TTM
- -0.86x
- ROE TTM
- 78.98%
- ROA TTM
- -207.90%
- Debt To Equity
- -1.34x
- Free Cash Flow TTM
- $-65.35M
- Net Revenue TTM Growth 1Y
- 6.81%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Karyopharm Therapeutics Inc. in?
Karyopharm Therapeutics Inc. (KPTI) operates in the Pharmaceutical Preparations industry.
What exchange does KPTI trade on?
Karyopharm Therapeutics Inc. (KPTI) trades on the Nasdaq.
Where is Karyopharm Therapeutics Inc. incorporated?
Karyopharm Therapeutics Inc. is incorporated in DE.
When was Karyopharm Therapeutics Inc. (KPTI)'s most recent SEC filing?
Karyopharm Therapeutics Inc. (KPTI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is KPTI's market cap?
Karyopharm Therapeutics Inc. (KPTI) has a market capitalization of $282.72M as of 2026-06-30.
What is KPTI's EPS (earnings per share)?
Karyopharm Therapeutics Inc. (KPTI)'s trailing twelve month EPS is $-7.77 as of 2026-06-30.
What is KPTI's ROE (return on equity)?
Karyopharm Therapeutics Inc. (KPTI)'s trailing twelve month Return on Equity (ROE) is 78.98% as of 2026-06-30.
What is KPTI's ROA (return on assets)?
Karyopharm Therapeutics Inc. (KPTI)'s trailing twelve month Return on Assets (ROA) is -207.90% as of 2026-06-30.
What is KPTI's EV/EBITDA?
Karyopharm Therapeutics Inc. (KPTI)'s trailing twelve month EV/EBITDA is -4.29x as of 2026-06-30.